HAVCR2 and acute myeloid leukemia: Co-blockade of Tim-3 and another checkpoint receptors have shown an increased tumor cell clearance resulting in a higher efficacy of combinational immunotherapy for AML treatment in mouse models (Fourcade J et al., 2010; Zhoud et al., 2011).